October 22, 2019
Authored and Edited by Kathryn R. Judson; Sydney R. Kestle; Elizabeth D. Ferrill
In OSI Pharmaceuticals, LLC v. Apotex Inc., No. 2018-1925 (Fed. Cir. Oct. 4, 2019), the Federal Circuit reversed the PTAB’s determination that certain claims of U.S. Patent No. 6,900,221 were unpatentable as obvious.
Before the Board, Apotex sought an IPR to cancel several claims of OSI’s ’221 patent, covering the use of erlotinib to treat non-small cell lung cancer (NSCLC). Apotex argued obviousness in light of prior art and OSI’s 10-K disclosure with the Securities and Exchange Commission. The Board agreed with Apotex and held that the prior art references would have provided “a person of ordinary skill with a reasonable expectation of success in using erlotinib to treat NSCLC in a mammal.”
On appeal, the Federal Circuit reversed the Board’s obviousness determination, holding that the Board misinterpreted the prior art to “teach more than substantial evidence supports.” The Court reasoned that the references offer “no more than hope,” and that no information about erlotinib’s success in treating NSCLC was disclosed. The Court made clear a reasonable factfinder could not find a reasonable expectation of success in this case.
Patent Trial and Appeal Board (PTAB), Obviousness (35 USC § 103), Person of Ordinary Skill in the Art (PHOSITA), 2019 Top Insights
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.